Neutrophil Gelatinase-Associated Lipocalin Is Not Associated with Tacrolimus-Induced Acute Kidney Injury in Liver Transplant Patients Who Received Mycophenolate Mofetil with Delayed Introduction of Tacrolimus
Authors:
- Mio FukudaMFMio Fukuda
- Kimitaka SuetsuguKSKimitaka Suetsugu
- Soichiro TajimaSTSoichiro Tajima
- Yurie KatsubeYKYurie Katsube
- Hiroyuki WatanabeHWHiroyuki Watanabe
- Noboru HaradaNHNoboru Harada
- Tomoharu YoshizumiTYTomoharu Yoshizumi
- Nobuaki EgashiraNENobuaki Egashira
- Masaki MoriMMMasaki Mori
- Satohiro MasudaSatohiro Masuda
Open Access
- 25 June 2019
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (12) , 3103
Abstract
Tacrolimus is widely used as an immunosuppressant in liver transplantation, and tacrolimus-induced acute kidney injury (AKI) is a serious complication. The urinary neutrophil gelatinase-associated lipocalin (NGAL) level has been linked to tacrolimus-induced AKI in patients starting tacrolimus treatment the morning after liver transplantation. Here we tested this association using a different immunosuppression protocol: Mycophenolate mofetil administration beginning on Postoperative Day 1 and tacrolimus administration beginning on Postoperative Day 2 or 3. Urine samples were collected from 26 living donor liver transplant recipients before (Postoperative Day 1) and after (Postoperative Day 7 or 14) tacrolimus administration. NGAL levels were measured via enzyme-linked immunosorbent assays, as were those of three additional urinary biomarkers for kidney diseases: Monocyte chemotactic protein-1 (MCP-1), liver-type fatty acid-binding protein (L-FABP), and human epididymis secretory protein 4 (HE4). HE4 levels after tacrolimus administration were significantly higher in patients who developed AKI (n = 6) than in those who did not (n = 20), whereas NGAL, MCP-1, and L-FABP levels did not differ significantly before or after tacrolimus administration. These findings indicate that NGAL may not be a universal biomarker of AKI in tacrolimus-treated liver transplant recipients. To reduce the likelihood of tacrolimus-induced AKI, our immunosuppression protocol is recommended.Keywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology (18H02588)
This publication has 35 references indexed in Scilit:
- Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosisNature Medicine, 2013
- Urinary neutrophil gelatinase-associated lipocalin as a marker of acute kidney injury after orthotopic liver transplantationNephrology Dialysis Transplantation, 2011
- Next-generation biomarkers for detecting kidney toxicityNature Biotechnology, 2010
- Predicting Cisplatin-Induced Acute Kidney Injury by Urinary Neutrophil Gelatinase-Associated Lipocalin Excretion: A Pilot Prospective Case-Control StudyNephron Clinical Practice, 2010
- Comparative Analysis of Novel Noninvasive Renal Biomarkers and Metabonomic Changes in a Rat Model of Gentamicin NephrotoxicityToxicological Sciences, 2009
- Urinary Biomarkers for Sensitive and Specific Detection of Acute Kidney Injury in HumansClinical and Translational Science, 2008
- Urine NGAL Predicts Severity of Acute Kidney Injury After Cardiac SurgeryClinical Journal of the American Society of Nephrology, 2008
- NGAL is an early predictive biomarker of contrast-induced nephropathy in childrenPediatric Nephrology, 2007
- An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patientsPharmacology & Therapeutics, 2006
- Assessing renal function in cirrhotic patients: Problems and pitfallsAmerican Journal of Kidney Diseases, 2003